|1.||Li, Szu-Yuan: 1 article (01/2015)|
|2.||Ou, Shuo-Ming: 1 article (01/2015)|
|3.||Yang, Chih-Yu: 1 article (01/2015)|
|4.||Chao, Pei-Wen: 1 article (01/2015)|
|5.||Shih, Chia-Jen: 1 article (01/2015)|
|6.||Chen, Yung-Tai: 1 article (01/2015)|
|7.||Wu, Yueh-Lin: 1 article (01/2015)|
|8.||Kuo, Shu-Chen: 1 article (01/2015)|
|9.||Raile, Klemens: 1 article (03/2014)|
|10.||Wells, B J: 1 article (03/2014)|
06/01/2003 - "In 1995, several new molecules under study as potential insulinotropic agents for the treatment of non-insulindependent diabetes mellitus were identified as analogs of meglitinide, previously known as the non-sulfonylurea moiety of glibenclamide. "
01/01/2012 - "Many of the therapeutic agents used to treat diabetes mellitus have the ability to lower blood glucose to dangerous concentrations; these include the sulfonylurea, meglitinide, and thiazolidinedione drug classes. "
|2.||Type 2 Diabetes Mellitus (MODY)
03/01/2014 - "Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3)."
01/01/2007 - "The aim of this review was to assess the effects of meglitinide analogues in patients with type 2 diabetes mellitus. "
01/01/2007 - "Meglitinide analogues for type 2 diabetes mellitus."
01/01/2003 - "Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus."
11/01/2000 - "Meglitinide analogues in the treatment of type 2 diabetes mellitus."
|3.||Hypoglycemia (Reactive Hypoglycemia)
03/01/2014 - "In adults with HNF1A-MODY, meglitinide analogues achieve lower postprandial glucose levels and pose a lower risk of delayed hypoglycemia compared with sulfonylureas. "
05/01/2010 - "Hypoglycemia often occurs with insulin, sulfonylureas, or meglitinide therapy. "
01/01/2003 - "The meglitinide analogs offer the advantage over the long-acting antihyperglycemic sulfonylurea glibenclamide of minimizing the risk of undesirable hypoglycemia."
04/01/1983 - "The secretion of PP was stimulated by HB 699 before the onset of hypoglycemia, whereas, following glipizide administration, PP secretion increased only after the onset of hypoglycemia. "
03/01/2013 - "Meglitinide analogs are limited by their frequent dosing, expense and hypoglycemia (repaglinide > nateglinide), while AGIs are also limited by their dosing schedule and GI side-effect profile. "
03/01/2014 - "To analyse the association between cancer incidence and oral diabetes therapy (biguanide, sulphonylurea, thiazolidinedione and meglitinide) in men and women with type 2 diabetes mellitus. "
03/01/2014 - "Comparison of insulin secretagogues (sulphonylurea and meglitinide) versus insulin sensitizers (biguanide and thiazolidinedione) demonstrated a 21% decreased cancer risk in insulin sensitizers [HR 0.79 (95% CI 0.64-0.98) in the adjusted analysis]. "
01/01/1982 - "Employing the test model which we developed for the investigation of platelet adhesiveness and aggregation in vivo, experiments demonstrated that the sulfonyl urea derivatives, glibenclamide, gliclazide, and HB 180, as well as the carboxylic acid derivative, meglitinide, are able to inhibit, in a dose-dependent relationship, the adherence of i.v. injected Walker-256-carcinosarcoma cells to the vascular endothelium of the rat mesentery, as well as to reduce significantly the rate of instantly occurring terminal tumor cell embolism of the lung. "
11/01/2006 - "For patients with postprandial hyperglycemia, a-glucosidase inhibitors and meglitinide analogs should be considered. "
01/01/2000 - "alpha-Glucosidase inhibitors slow carbohydrate absorption, resulting in reduced postprandial hyperglycemia; thiazolidinediones increase insulin sensitivity, especially in muscle and adipocytes; metformin decreases hepatic gluconeogenesis; sulfonylureas result in prolonged increases in insulin secretion; and meglitinide causes rapid, short-lived increases in insulin secretion. "
|5.||alpha-Glucosidases (Acid Maltase)